Is XERS or ZYBT more undervalued in 2026?

CirclFi compares Xeris Biopharma Holdings, Inc. (XERS) and Zhengye Biotechnology Holding L (ZYBT) using 13 institutional-grade valuation models. XERS has a Quality of Company score of 8.6/10 while ZYBT scores 6.3/10.

Which is a better buy — XERS or ZYBT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XERS and ZYBT valuations compare?

XERS at $6.32 and ZYBT at $0.81 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XERS vs ZYBT Valuation Comparison 2026 — Intrinsic Value Analysis

XERS

Drug Manufacturers - Specialty & Generic

Xeris Biopharma Holdings, Inc.

Quality

8.6

out of 10

Value Trap

LOW

Price

$6.32

Last close

Models

11/13

Active

ZYBT

Drug Manufacturers - Specialty & Generic

Zhengye Biotechnology Holding L

Quality

6.3

out of 10

Value Trap

SAFE

Price

$0.81

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	XERS Fair Value	XERS Upside	ZYBT Fair Value	ZYBT Upside
Bayesian DCF	Intrinsic	$1.44	-77.1%	$0.66	-18.7%
Earnings Power Value	Intrinsic	$0.13	-97.9%	$0.82	-10.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XERS vs ZYBT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XERS vs ZYBT — Which Stock Is More Undervalued?

XERS scores higher with a 8.6/10 quality rating vs ZYBT's 6.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Xeris Biopharma Holdings, Inc. (XERS) and Zhengye Biotechnology Holding L (ZYBT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XERS currently trades at $6.32 with a QOC of 8.6/10, while ZYBT trades at $0.81 with a QOC of 6.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).